CD274 and non-small cell lung carcinoma: Both IMpower010 and KEYNOTE-091 trials were conducted on patients with stage IB-IIIA (AJCC 7th edition staging) fully resected lesions of NSCLC patients with fully resected lesions in stage IB-IIIA (AJCC 7th edition staging), and the final results of the phase III clinical study of postoperative adjuvant immunotherapy showed that patients in the immunotherapy group had a disease-free survival benefit regardless of the level of PD-L1 expression (74, 75).